The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; none of the 23 sources its claims cite is checked for support yet.
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Open accessAbstract
BACKGROUND: Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be evaluated longitudinally. OBJECTIVE: To characterize cross-sectionally and longitudinally clinical measures in normal controls, subjects with MCI, and subjects with mild Alzheimer disease (AD) to enable the assessment of the utility of neuroimaging and chemical biomarker measures. METHODS: A total of 819 subjects (229 cognitively normal, 398 with MCI, and 192 with AD) were enrolled at baseline and followed for 12 months using standard cognitive and functional measures typical of clinical trials. RESULTS: The subjects with MCI were more memory impaired than the cognitively normal subjects but not as impaired as the subjects with AD. Nonmemory cognitive measures were only minimally impaired in the subjects with MCI. The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year. Approximately 50% of the subjects with MCI were on antidementia therapies. There was minimal movement on the Alzheimer's Disease Assessment Scale-Cognitive Subscale for the normal control subjects, slight movement for the subjects with MCI of 1.1, and a modest change for the subjects with AD of 4.3. Baseline CSF measures of Abeta-42 separated the 3 groups as expected and successfully predicted the 12-month change in cognitive measures. CONCLUSION: The Alzheimer's Disease Neuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics. The 12-month progression rate of MCI was as predicted, and the CSF measures heralded progression of clinical measures over 12 months.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This ADNI clinical characterization paper reports baseline and 12-month clinical, cognitive, and CSF biomarker data for 819 participants: 229 cognitively normal, 398 with MCI, and 192 with mild AD. It shows expected group differences at baseline, a 16.5% 12-month MCI-to-AD progression rate, and baseline CSF Aβ-42 predicting 12-month cognitive change in normal and MCI groups.
Key findings
- At baseline, ADAS-Cog total scores were 6.2 ± 2.9 in controls, 11.5 ± 4.4 in MCI, and 18.6 ± 6.3 in AD (p < 0.001); MCI subjects were most impaired on memory items and only mildly impaired in nonmemory domains.
- Over 12 months, 64 of 398 MCI subjects progressed to AD, a rate of 16.5% (95% CI 11.9%–20.5%); normal controls progressed to MCI at an estimated 1.4% (95% CI 0%–3.2%).
- ADAS-Cog 12-month change was −0.5 ± 3.0 in controls, 1.1 ± 4.4 in MCI, and 4.3 ± 6.6 in AD (p < 0.001).
- Baseline CSF Aβ-42 decreased across groups (controls 206 ± 5, MCI 164 ± 4, AD 143 ± 4 pg/mL; p < 0.001), and higher baseline Aβ-42 was associated with better ADAS-Cog performance and smaller 12-month change in normal subjects and MCI.
Methods
- Multicenter ADNI cohort of 819 subjects aged 55–90 enrolled at baseline and classified as cognitively normal, MCI, or mild AD using standard clinical, cognitive, and functional criteria; subjects were followed for 12 months with cognitive and functional measures, MRI/PET in subsets, and lumbar puncture in a minimum of 20% per site.
- Baseline group comparisons used nonparametric tests (Kruskal-Wallis) with Hochberg multiple comparisons and exact tests for proportions; 12-month change was summarized as conversion proportion, baseline-to-12-month mean or percent difference, and rate per year from mixed-effects regression models.
- Annual conversion rates were estimated using a hybrid interval-censored method; CSF Aβ-42 was related to diagnosis, ADAS-Cog performance, and 12-month ADAS-Cog change.
Limitations
- The paper states that a 12-month change period is not sufficient to draw conclusions about the likelihood of clinical change, and that the ADNI cohort likely does not represent “typical” community subjects because participants were more highly educated, mostly white, and had a high proportion of APOE4 carriers in the MCI and AD groups.
- The paper also states that the MCI criteria required a stringent degree of memory impairment, so these subjects were likely further along the clinical spectrum and more likely to progress than less-impaired MCI subjects.
- Evident from the text: CSF analyses were limited to subsets (baseline n = 114 controls, 199 MCI, 102 AD), and some subjects lacked 12-month follow-up diagnoses (17 controls and 41 MCI subjects), which limits interpretation of conversion and biomarker results.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
53 Own result · 8 Sources not found · 8 Own interpretation · 5 No basis given · 3 Not checked yet · 3 Own method
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“successfully predicted the 12-month change in cognitive measures.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plaincorrelationaln = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“but they looked more like the AD group for change in digit span, category fluency, and trail making”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nonmemory cognitive measures were only minimally impaired in the subjects with MCI.”
- Also stated in: § RESULTS Baseline characteristics. · hedged
“The neuropsychological battery indicated that, in general, subjects with MCI were more impaired than controls on the memory items and were only mildly impaired in nonmemory domains (table 3).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § RESULTS Baseline characteristics. · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The sub-jects with AD were impaired in virtually all of the cognitive areas tested.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These scores indicated, however, that the subjects with MCI gained most of their error points on memory items.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Baseline CSF measures of A-42 separated the 3 groups as expected”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plaincorrelationaln = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The next greatest area of impairment for the subjects with MCI resulted from the executive function domain.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The subjects with MCI also remained relatively stable as a group, and the subjects with mild AD showed a decline on most of these measures.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The interaction of A-42 and time also had a significant effect on ADAS-Cog scores in subjects with MCI ( p ϭ 0.00), but not in normal subjects.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 14
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CDR sum of the boxes essentially did not change in the normal control group (0.1) and increased by approximately 0.7 points in the subjects with MCI and 1.5 points in the subjects with AD ( p Ͻ 0.001).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The subjects with MCI were more memory impaired than the cognitively normal subjects but not as impaired as the subjects with AD.”
- Also stated in: § RESULTS Baseline characteristics. · hedged
“These scores indicated, however, that the subjects with MCI gained most of their error points on memory items.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § RESULTS Baseline characteristics. · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In general, the normal group stayed nearly the same, and the AD group worsened significantly compared to the normal controls.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and more like the normal controls for the clock test and global CDR.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, subjects with MCI had a mean total Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) score of 11.5, while the normal control subjects had a score of 6.2 and the subjects with mild AD had a score of 18.7 ( p Ͻ 0.001, table 3).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“cholinesterase inhibitors-normal controls 0%, subjects with MCI 43.7%, subjects with AD 84.9%”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 819 subjects were recruited and received a baseline evaluation as part of the ADNI study.”
- Also stated in: § RESULTS Baseline characteristics. · plain
“There were 229 normal control subjects, 398 subjects with MCI, and 192 subjects with mild AD enrolled.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § RESULTS Baseline characteristics. · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The estimated premorbid verbal IQ of these subjects was quite high, at almost 120 for the normal control subjects, 116 for the subjects with MCI, and 114 for the subjects with AD.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
hedgedn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In all cases except the Hachinski Scale and Geriatric Depression Scale, the mean scores for the 3 groups differed significantly at p Ͻ 0.001, with normal controls performing best, subjects with AD worst, and subjects with MCI in the middle.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The MCI group was more variable; in most cases they worsened more than the normal group but not as much as the AD group”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Approximately 50% of the subjects with MCI were on antidementia therapies.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Most of the subjects in the study were white, and this was approximately equivalent across the groups.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was minimal movement on the Alzheimer's Disease Assessment Scale-Cognitive Subscale for the normal control subjects, slight movement for the subjects with MCI of 1.1, and a modest change for the subjects with AD of 4.3.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As shown in table 2, the mean age of the 3 groups was equivalent at approximately 75 years.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plainn = 819- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“there were more men than women in the MCI group (64.6% men vs 35.4% women).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
plainn = 398- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“There was somewhat less variability on the global measures, while some of the individual neuropsychological tests such as the AVLT showed considerable variability among the subjects despite relatively modest mean group changes.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“CSF A-42 levels were assessed at baseline and were correlated with clinical diagnoses, performance on the ADAS-Cog, and changes in performance on the ADAS-Cog over 1 year (table 3).”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Delayed recall improved by 5.3% in the normal control group and declined by 4.8% in the subjects with MCI and 7.2% in the subjects with AD.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“As such, the baseline characteristics of the subjects indicated that the 3 groups were generally well educated, intelligent, and mostly white, and perform in a fashion similar to subjects recruited for typical clinical trials.[25][26][27][28]”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CSF A-42 data correlated with the diagnostic groups in the expected fashion with levels being lower in the subjects with MCI than in the normal subjects.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: CSF Aβ-42 level is a valid biomarker of Alzheimer's disease pathology and progression.
None of the sources cited for this claim have been checked yet.
In the paper
“They tend to be more highly educated and the proportion of APOE4 carriers was quite high in the MCI and AD groups but is consistent with subjects recruited for clinical trials.25”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“On the memory measures such as the AVLT, there was virtually no change across 12 months in learning in the normal control group with a decreased learning of 1.3 items in the subjects with MCI and 3.7 fewer items learned in the AD group.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“An additional 8 subjects with MCI reverted to a normal classification over that interval, and 41 did not have a follow-up diagnosis.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
plainn = 398- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“may allow detection of the neurodegenerative process at an earlier point in the spectrum”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
What the sources say
- Not matchedcites [6]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [7]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [8]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All hypothesis tests were 2-sided at level 0.05, and models were validated both graphically and analytically.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Data analysis.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Most investigators believe that Alzheimer disease (AD) is a slowly evolving process that likely begins years to decades before the clinical symptoms are manifest.1”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
What the sources say
- Not matchedcites [1]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“A 12month change period is not a sufficient amount of time to draw conclusions regarding the likelihood of clinical change.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“has been a target for clinical trials.[2][3][4][5]”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
What the sources say
- Not matchedcites [2]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [3]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [4]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [5]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The diagnostic conversions over the 12-month period must be viewed with some caution.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This might be a useful technique to reduce the numbers of subjects used in clinical trials to detect a clinical effect of therapeutic interventions.”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > DISCUSSION
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence.
- Rests on an assumption: CSF Aβ-42 level is a valid biomarker of Alzheimer's disease pathology and progression.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“Mild cognitive impairment (MCI) represents an attempt to characterize subjects at an early clinical phase”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Abstract
What the sources say
- Not matchedcites [2]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [3]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [4]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [5]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Not matched
The paper relies on this without support.
The expected 12-month progression rate for MCI was approximately 16.5% per year.
“The 12-month progression rate of MCI was as predicted”
“The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year.”
The paper relies on this without support.
The baseline characteristics observed in the recruited cohorts matched the characteristics anticipated for normal, MCI, and AD cohorts.
“The Alzheimer's DiseaseNeuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics.”
The paper relies on this without support.
The MCI subjects have an underlying Alzheimer's disease process that drives clinical progression.
“As such, these subjects were likely further down the clinical spectrum with respect to the underlying AD process such that they would be more likely to progress than subjects with less impairment in the MCI spectrum.”
The paper relies on this without support.
CSF Aβ-42 level is a valid biomarker of Alzheimer's disease pathology and progression.
“The CSF A-42 data correlated with the diagnostic groups in the expected fashion with levels being lower in the subjects with MCI than in the normal subjects.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Another issue is that the vast majority of data from PET and CSF are from selected participants recruited through tertiary care dementia centers [176].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [176]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
“Among the 398 subjects with MCI at baseline, 64 progressed to AD at 12 months”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
“Table 5 Baseline measures on subjects according to progression status at 1 year Assortment variable Nonprogressors, mean ؎ SD (n ؍ 329) Progressors, mean ؎ SD (n ؍ 69)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
“the subjects with mild AD had a score of 18.7”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
“ADAS-Cog total 6.2 Ϯ 2.9 11.5 Ϯ 4.4 18.1 18.6 Ϯ 6.3 14.0 Ͻ0.001 a, b, c”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
“subjects with MCI (r ϭ Ϫ0.22; 95% CI Ϫ0.035 to Ϫ0.08)”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > Concomitant medications.
“95% CI Ϫ0.035 to Ϫ0.08”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
“In all cases except the Hachinski Scale and Geriatric Depression Scale, the mean scores for the 3 groups differed significantly at p Ͻ 0.001”
§ Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization > RESULTS Baseline characteristics.
“GDS Score 0.8 Ϯ 1.1 1.6 Ϯ 1.4 7.3 1.7 Ϯ 1.4 0.6 Ͻ0.001 a, b”
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Development and validation of a geriatric depression screening scale: a preliminary report
Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, V. O. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90033-4 · Cited by 15,025
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Self-citationRandom-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923
VALIDITY OF THE TRAIL MAKING TEST AS AN INDICATOR OF ORGANIC BRAIN DAMAGE
Reitan, R. M. (1958) · Perceptual and Motor Skills · doi:10.2466/pms.1958.8.3.271 · Cited by 8,167
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Self-citationThe Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Gauthier, S. G., Reisberg, ., Zaudig, M., Petersen, R. C., Ritchie, K. A., Broich, K., Belleville, S., Brodaty, H., Bennett, D. A., Chertkow, H. M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 4,094
Self-citationL’examen Clinique en Psychologie
Rubé, P. (1959) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1959.13.4.989 · Cited by 3,299
Cited by
Sorted by citations
Items 1,001–1,100 of 2,570
Mild cognitive impairment classification using combined structural and diffusion imaging biomarkers
Pérez-González, J., Jiménez-Ángeles, L., Saavedra, K. R., Morales, E. B., Medina-Bañuelos, V., & Initiative, A. D. N. (2021) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ac0e77 · Cited by 15
Suresha, H. S., & Parthasarathy, S. S. (2021) · Distributed and Parallel Databases · doi:10.1007/s10619-021-07345-y · Cited by 16
Duff, K. M., & on behalf of the ADNI investigators (2021) · Neurology · doi:10.1212/wnl.0000000000012587 · Cited by 15
Nakahata, N., Nakamura, T., Kawarabayashi, T., Seino, Y., Ichii, S., Ikeda, Y., Amari, M., Takatama, M., Murashita, K., Ihara, K., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210699 · Cited by 14
Ren, W., Ji, B., Guan, Y., Cao, L., & Ni, R. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.771982 · Cited by 16
Cross-sectional associations of CSF tau levels with Rey’s AVLT: A recency ratio study.
Bruno, D., Zinkunegi, A. J., Pomara, N., Zetterberg, H., Blennow, K., Koscik, R. L., Carlsson, C. M., Bendlin, B. B., Okonkwo, O. C., Hermann, B. P., et al. (2022) · Neuropsychology · doi:10.1037/neu0000821 · Cited by 16
Richards, K. C., Lozano, A. J., Morris, J. L., Moelter, S. T., Ji, W., Vallabhaneni, V., Wang, Y., Chi, L., Davis, E. M., Cheng, C. I.-F., et al. (2023) · The Journals of Gerontology Series A · doi:10.1093/gerona/glad099 · Cited by 15
Mapping CSF biomarker profiles onto NIA–AA guidelines for Alzheimer’s disease
Alexopoulos, P., Roesler, J., Thierjung, N., Werle, L., Buck, D., Yakushev, I. Y., Gleixner, L. S., Kagerbauer, S. M., Ortner, M., Grimmer, T., et al. (2015) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-015-0628-7 · Cited by 17
“They were independent in their activities of daily living [12, 14].”
BackgroundMethodBattle against Alzheimer's Disease
Paquerault, S. (2012) · Academic Radiology · doi:10.1016/j.acra.2012.02.003 · Cited by 15
For debate: substituting placebo controls in long-term Alzheimer's prevention trials
Spiegel, R., Berres, M., Miserez, A. R., Monsch, A. U., & Initiative, T. A. D. N. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt68 · Cited by 15
Alzheimer risk genes modulate the relationship between plasma apoE and cortical PiB binding
Lazaris, A. S., Hwang, K., Goukasian, N., Ramirez, L. M., Eastman, J. A., Blanken, A. E., Teng, E., Gylys, K. H., Cole, G. M., Saykin, A. J., et al. (2015) · Neurology Genetics · doi:10.1212/nxg.0000000000000022 · Cited by 15
Self-citationKnowledge and Attitudes in Alzheimer’s Disease in a Cohort of Older African Americans and Caucasians
Howell, J. C., Soyinka, O., Parker, M., Jarrett, T. L., Roberts, D. L., Dorbin, C. D., & Hu, W. T. (2015) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317515619037 · Cited by 15
HLA-A2 Alleles Mediate Alzheimer’s Disease by Altering Hippocampal Volume
Initiative, A. D. N., Wang, Z.-X., Wang, H.-F., Tan, L., Sun, F.-R., Tan, C., Tan, C.-C., Jiang, T., Tan, L., & Yu, J. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9832-3 · Cited by 15
Which MCI Patients Should be Included in Prodromal Alzheimer Disease Clinical Trials?
Grill, J. D., Nuño, M. M., & Gillen, D. L. (2019) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000303 · Cited by 15
“13 MCI was de fi ned using Petersen criteria.”
Voices from the field: Expert reflections on mild cognitive impairment
Peters, K. R., & Katz, S. (2015) · Dementia · doi:10.1177/1471301214562135 · Cited by 16
“…(e.g. see De Santi et al., 2001; Pennanen et al., 2004; Xu et al., 2000), CSF levels of amyloid and/or tau (e.g. see Andreasen et al., 1999; Petersen et al., 2010; Visser et al., 2009) and PiB-PET measures of amyloid deposition in the brain (e.g. see Forsberg et al., 2008; Jack et al.,…”
BackgroundFuzzy RNN Model-Based Classification of Alzheimer’s Disease and Dementia Using Brain EEG Signals
Sreedhar, J., Pattapu, U., Reddy, M. B., Dara, S., Agrawal, K. K., Kumar, P., Ali, J., & Alkhayyat, A. H. (2025) · IEEE Transactions on Consumer Electronics · doi:10.1109/tce.2025.3570375 · Cited by 14
Murray, M. E., Smith, C., Menon, V., Keene, C. D., Lein, E. S., Hawrylycz, M., Aguzzi, A., Benedetti, B. L., Brose, K., Caetano-Anollés, K., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.06.014 · Cited by 16
Expert Group Meeting on Aphasia
Pauranik, A., George, A., Sahu, A., Nehra, A., Paplikar, A., Bhat, C. G., Krishnan, G., Kaur, H., Saini, J., Suresh, P. A., et al. (2019) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_330_18 · Cited by 16
Lou, C., Habes, M., Illenberger, N., Ezzati, A., Lipton, R. B., Shaw, P. A., Stephens‐Shields, A. J., Akbari, H., Doshi, J. J., Davatzikos, C. A., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab264 · Cited by 13
“- loni.usc.edu) on 283 subjects with mild cognitive impairment (MCI) who underwent serial MRIs at 1.5 T. 9,17 The ADNI was launched in 2003 as a public– private partnership, led by Principal Investigator Michael W. Weiner, MD.”
InfluentialQiu, T., Xie, F., Zeng, Q., Shen, Z., Du, G., Xu, X., Wang, C., Li, X., Luo, X., Li, K., et al. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13852 · Cited by 14
Bernier, R. A., Banks, S. J., Panizzon, M. S., Andrews, M., Jacobs, E. G., Galasko, D. R., Shepherd, A. L., Akassoglou, K., Sundermann, E. E., & Initiative, A. D. N. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12284 · Cited by 13
Huang, J., Stein, T. D., Wang, Y., Ang, T. F. A., Tao, Q., Lunetta, K. L., Massaro, J., Akhter‐Khan, S. C., Mez, J., Au, R., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12851 · Cited by 14
Chakraborty, D., Zhuang, Z., Xue, H., Fiecas, M. J. A., Shen, X., Initiative, A. D. N., & Pan, W. (2023) · Genes · doi:10.3390/genes14030626 · Cited by 15
“Alzheimer’s Disease Neuroimaging Initiative (ADNI) [3] is an ongoing research project on the development and progress of the disease.”
Development and validation of a deep-broad ensemble model for early detection of Alzheimer's disease
Ma, P., Wang, J., Zhou, Z., Chen, C. L. P., Initiative, T. A. D. N., & Duan, J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1137557 · Cited by 15
“On the basis of RVFLNN (Pao et al., 1994), Chen et al. proposed Broad Learning System (BLS) (Chen and Liu, 2017a,b).”
BackgroundMethodInfluentialXiaoliang, G., Ding, Y., Xu, W., Wang, D., Yu, H., Lin, Y., Chang, S., Zhang, Q., & Zhang, Y. (2023) · Journal of Neuroradiology · doi:10.1016/j.neurad.2023.09.002 · Cited by 14
Zheng, L., Rubinski, A., Denecke, J., Luan, Y., Smith, R. A., Strandberg, O. T., Stomrud, E., Ossenkoppele, R., Svaldi, D. O., Higgins, I. A., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26818 · Cited by 15
Lock, C., Tan, N. S. M., Long, I. J., & Keong, N. C. H. (2024) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2023.1286266 · Cited by 16
Huynh, N., Yan, D., Ma, Y., Wu, S., Long, C., Sami, M. T., Almudaifer, A. I., Jiang, Z., Chen, H., Dretsch, M. N., et al. (2024) · Brain Sciences · doi:10.3390/brainsci14050456 · Cited by 15
“…models on FC-based brain networks for discriminating healthy subjects from individuals diagnosed with ADHD (ADHD-200 [19] dataset), autism (ABIDE-II [20] dataset instead of ABIDE-I used in our previous work), PTSD (acquired in-house but publicly shared [21]), and Alzheimer’s (ADNI [22]) datasets.”
BackgroundMethodShoji, M. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/564321 · Cited by 15
Barber, R. C., Phillips, N., Tilson, J. L., Huebinger, R. M., Shewale, S., Koenig, J. L., Mitchel, J. S., O’Bryant, S. E., Waring, S. C., Diaz-Arrastia, R. R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142360 · Cited by 14
The impact of PICALM genetic variations on reserve capacity of posterior cingulate in AD continuum
Xu, W., Wang, H.-F., Tan, L., Tan, M., Tan, C.-C., Zhu, X., Miao, D., Yu, W.-J., Jiang, T., Tan, L., et al. (2016) · Scientific Reports · doi:10.1038/srep24480 · Cited by 14
Self-citationAlzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal
Vermunt, L., van Paasen, A. J. L., Teunissen, C. E., Scheltens, P., Visser, P. J., Tijms, B. M., & Initiative, A. D. N. (2019) · Neurology · doi:10.1212/wnl.0000000000007609 · Cited by 14
“From the individuals with at least 2 years clinical follow-up, we selected all individuals with prevalent and incident MCI reverting to NC with additional follow-up after reversion.(8) The ADNI was launched in 2003 as a public–private partnership, led by Principal Investigator Michael W.”
MethodIs the Mini-Mental State Examination the best cognitive screening test for less educated people?
Scarabelot, L. F., Monteiro, M. D. M., Rubert, M. C. D. S., & Zétola, V. D. H. F. (2019) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20190043 · Cited by 15
Phillips, M. L., Stage, E., Lane, K. A., Gao, S., Risacher, S. L., Goukasian, N., Saykin, A. J., Carrillo, M. C., Dickerson, B. C., Rabinovici, G. D., et al. (2019) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000504341 · Cited by 14
Automated MRI-based volumetry of basal ganglia and thalamus at the chronic phase of cortical stroke
Baudat, C., Maréchal, B., Jerez, R. A. C., Kober, T., Meuli, R. A., Hagmann, P., Michel, P., Maeder, P. P., & Dunet, V. (2020) · Neuroradiology · doi:10.1007/s00234-020-02477-x · Cited by 16
Kröll, J., Eickhoff, S. B., Hoffstaedter, F., et al. (2020) · IEEE Congress on Evolutionary Computation (CEC) · doi:10.1109/cec48606.2020.9185843 · Cited by 14
Reliable change in neuropsychological test scores is associated with brain atrophy in older adults
Lin, S. S. ‐., Fletcher, E. M., Gavett, B. E., & Initiative, A. D. N. (2020) · Journal of Neuropsychology · doi:10.1111/jnp.12226 · Cited by 14
Xu, W., Initiative, A. D. N., Tan, C., Cao, X., & Tan, L. (2020) · Aging · doi:10.18632/aging.103814 · Cited by 16
Regional Gray Matter Volume Identifies High Risk of Unsafe Driving in Healthy Older People
Yamamoto, Y., Yamagata, B., Hirano, J., Ueda, R., Yoshitake, H., Negishi, K., Yamagishi, M., Kimura, M., Kamiya, K., Shino, M., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.592979 · Cited by 15
“All participants were diagnosed as “cognitively normal” using the Alzheimer’s Disease Neuroimaging Initiative (ADNI) diagnostic classification: (1) Mini-Mental State Examination (MMSE) score between 24 and 30; (2), Clinical Dementia Rating (CDR) score of 0; (3) normal memory function measured by education-adjusted sco…”
MethodMihaescu, A. S., Kim, J., Masellis, M., Graff‐Guerrero, A., Cho, S. S., Christopher, L., Valli, M., Díez‐Cirarda, M., Koshimori, Y., & Strafella, A. P. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24760 · Cited by 14
P-tau and neurodegeneration mediate the effect of β-amyloid on cognition in non-demented elders
Ma, L., Hu, H., Wang, Z.-T., Ou, Y., Dong, Q., Tan, L., & Yu, J. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00943-z · Cited by 16
Stage, E., Svaldi, D. O., Sokolow, S., Risacher, S. L., Marosi, K., Rotter, J. I., Saykin, A. J., Apostolova, L. G., & Initiative, A. D. N. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12168 · Cited by 13
Detection of dementia progression from functional activities data using machine learning techniques
Thabtah, F., Ong, S., & Peebles, D. (2022) · Intelligent Decision Technologies · doi:10.3233/idt-220054 · Cited by 15
“The datasets used in this research, ADNI-Merge and FAQ-sheet, are obtained from the ADNI data repository [54] after the approval of data access.”
Cuberas‐Borrós, G., Roca, I., Castell‐Conesa, J., Núñez, L., Boada, M., López, O. L., Grifols, C., Barceló, M., Pareto, D., & Páez, A. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05915-5 · Cited by 14
Cao, Q.-L., Initiative, A. D. N., Sun, Y., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220128 · Cited by 14
Mutual Information Neural Estimation for Unsupervised Multi-Modal Registration of Brain Images
Snaauw, G., Sasdelli, M., Maicas, G., Lau, S., Verjans, J. W. H., Jenkinson, M., & Carneiro, G. (2022) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc48229.2022.9871220 · Cited by 14
Polygenic Effect on Tau Pathology Progression in Alzheimer's Disease
Rubinski, A., Frerich, S., Malik, R., Franzmeier, N., Ramı́rez, A., Dichgans, M., Ewers, M., & Initiative, A. D. N. (2022) · Annals of Neurology · doi:10.1002/ana.26588 · Cited by 15
Initiative, A. D. N., Chiotis, K., Carter, S. F., Farid, K., Savitcheva, I., & Nordberg, A. K. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3115-5 · Cited by 16
Seo, E. H., Kim, S. H., Park, S. H., Kang, S., Choo, I. H., & Initiative, A. D. N. (2016) · Journal of Korean Medical Science · doi:10.3346/jkms.2016.31.2.286 · Cited by 15
EEG beta 2 power as surrogate marker for memory impairment: a pilot study
Kaiser, A. K., Doppelmayr, M. M., & Iglseder, B. (2017) · International Psychogeriatrics · doi:10.1017/s1041610217000758 · Cited by 14
Wang, X., Zhou, W., Ye, T., Lin, X., Zhang, J., & Initiative, T. A. D. N. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00036 · Cited by 13
“edu preserved activities of daily living, and were not demented (Petersen et al., 2010).”
Medical Informatics Platform (MIP): A Pilot Study Across Clinical Italian Cohorts
Redolfi, A., Francesco, S. D., Palesi, F., Galluzzi, S., Muscio, C., Castellazzi, G., Tiraboschi, P., Savini, G., Nigri, A., Bottini, G., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.01021 · Cited by 14
“To quantitatively measure the performance of the GB in discriminating MCI stable vs. converters, we used the longitudinal ADNI data set, which represented an indirect validation and a plausibility test of the MIP tool granting a 62% of accuracy.”
MethodInfluentialAdding cognition to AT(N) models improves prediction of cognitive and functional decline
O’Shea, D. M., Thomas, K. R., Asken, B. M., et al. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12174 · Cited by 14
Midorikawa, M., Suzuki, H., Suzuki, Y., Yamauchi, K., Sato, H., Nemoto, K., Sugano, Y., IWASAKI, H. O., Sekiya, M., Yatoh, S., et al. (2021) · Journal of Diabetes Research · doi:10.1155/2021/9961612 · Cited by 16
Ozdemir, C., Vashishath, Y., Bozdag, S., Initiative, A. D. N., Ozdemir, C., Vashishath, Y., & Bozdag, S. (2025) · Bioinformatics · doi:10.1093/bioinformatics/btaf313 · Cited by 13
Wang, T., Arnold, M., Huynh, K., Weinisch, P., Giles, C., Mellett, N. A., Duong, T., Marella, B., Nho, K. T., Livera, A. M. D., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105826 · Cited by 19
Zhang, S., Shu, H., Zhou, J., Rubin-Sigler, J., Yang, X. J., Liu, Y., Cooper‐Knock, J., Monte, E., Zhu, C., Tu, S., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02725-6 · Cited by 20
Brain Foundation Models: A survey on advancements in neural signal processing and brain discovery
Zhou, X., Liu, C., Chen, Z., Wang, K., Ding, Y., Jia, Z., & Wen, Q. (2025) · IEEE Signal Processing Magazine · doi:10.1109/msp.2025.3592356 · Cited by 39
Multimodal Wearable Biosensing Meets Multidomain AI: A Pathway to Decentralized Healthcare
Liu, C., Fan, H., Kim, M., Zhou, T., Yang, P., Zhao, L., Wang, Y., Che, Z., Liu, C., Li, B., et al. (2026) · Advanced Science · doi:10.1002/advs.202522900 · Cited by 20
Moon, S. W., Dinov, I. D., Hobel, S., Zamanyan, A., Choi, Y. C., Shi, R., Thompson, P. M., Toga, A. W., & Initiative, A. D. N. (2015) · Journal of Neuroimaging · doi:10.1111/jon.12252 · Cited by 13
Self-citationBloch, L., & Friedrich, C. M. (2021) · Lecture notes of the Institute for Computer Sciences, Social Informatics and Telecommunications Engineering · doi:10.1007/978-3-030-70569-5_18 · Cited by 13
Soluble amyloid-beta isoforms predict downstream Alzheimer’s disease pathology
Povala, G., Bellaver, B., Bastiani, M. A. D., Brum, W. S., Ferreira, P. C. L., Bieger, A., Pascoal, T. A., Benedet, A. L., Souza, D. O., Araújo, R., et al. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00712-3 · Cited by 14
Pan, R., Initiative, A. D. N., Luo, S., Huang, Q., Li, W., Cai, T., Lai, K., & Shi, X. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220002 · Cited by 13
“Participants in ADNI were aged between 55–90 (inclusive), diagnosed as cognitively normal (CN), MCI, or AD dementia, and underwent serial evaluation of functional, biomedical, neuropsychological, and clinical status at intervals [19].”
Survival Analysis of High-Dimensional Data With Graph Convolutional Networks and Geometric Graphs
Ling, Y., Liu, Z., & Xue, J. (2022) · IEEE Transactions on Neural Networks and Learning Systems · doi:10.1109/tnnls.2022.3190321 · Cited by 13
Rosa, A. P. D., Esposito, F., Valsasina, P., d’Ambrosio, A., Bisecco, A., Rocca, M. A., Tommasin, S., Marzi, C., Stefano, N. D., Battaglini, M., et al. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11479-z · Cited by 12
Sinclair, L. I., Ballard, C. G., & Initiative, A. D. N. (2022) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5858 · Cited by 13
“It has clinical data on >800 individuals including positron emission tomography and MRI.(26,27) Participants included in the trial had either early AD, MCI or normal cognition at baseline.”
Maddury, S., & Desai, K. (2023) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2023.1091506 · Cited by 13
“Along with investigating new proteins indicative of Alzheimer’s, new radiotracer biomarkers could be discovered to trace these new proteins.”
BackgroundInfluentialA Closer Look at Practice Effects in Mild Cognitive Impairment and Alzheimer’s Disease
Duff, K. M., Dixon, A. M., & Embree, L. M. (2023) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acad046 · Cited by 15
Dynamic Multi-Task Graph Isomorphism Network for Classification of Alzheimer’s Disease
Wang, Z., Lin, Z., Li, S., Wang, Y., Zhong, W., Wang, X., & Xin, J. (2023) · Applied Sciences · doi:10.3390/app13148433 · Cited by 15
“Furthermore, to better explore the relationship between human cognition and brain functional network, the AGE and PTGENDER fields from ADNI’s clinical information were utilized as age and gender labels [32].”
BackgroundMethodRajendrakumar, A. L., Arbeev, K. G., Bagley, O., Yashin, A. I., Ukraintseva, S. V., & Initiative, A. D. N. (2024) · BMC Neurology · doi:10.1186/s12883-024-03577-4 · Cited by 15
Yu, X., Sun, X., Wei, M., Deng, S., Zhang, Q., Guo, T., Shao, K., Zhang, M., Jiang, J., Han, Y., et al. (2024) · Research · doi:10.34133/research.0354 · Cited by 15
Distinct eye movement patterns to complex scenes in Alzheimer’s disease and Lewy body disease
Yamada, Y., Shinkawa, K., Kobayashi, M., Nemoto, M., Ota, M., Nemoto, K., & Arai, T. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1333894 · Cited by 15
Duff, K. M., Hammers, D. B., Koppelmans, V., King, J. B., & Hoffman, J. M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231392 · Cited by 13
“Overall, these findings are not surprising, as the existing literature has frequently reported on this same pattern in many prior studies [7, 26–29].”
Nelson, M. R., Keeling, E. G., Stokes, A. M., & Bergamino, M. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1440653 · Cited by 13
ASCHOPLEX: A generalizable approach for the automatic segmentation of choroid plexus
Visani, V., Veronese, M., Pizzini, F. B., Colombi, A., Natale, V., Marjin, C., Tamanti, A., Schubert, J. J., Althubaity, N., Bedmar-Gómez, I., et al. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.109164 · Cited by 18
“…of healthy controls (Human Connectome Project [43]), mild cognitive impairment, and Alzheimer Disease (Alzheimer’s Disease Neuroimaging Initiative [44]) and therefore it might be that different protocols and different pathologies (such as MS or Depression) require a different parameter…”
BackgroundPioneering new paths: the role of generative modelling in neurological disease research
Seiler, M., & Ritter, K. (2024) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-024-03016-w · Cited by 13
Lee, H., Kim, H. W., Lee, M., Kang, J., Kim, D., Lim, H. K., Lee, J., Kim, E., & Kim, R. E. Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-74622-y · Cited by 13
Cerebrovascular markers of WMH and infarcts in ADNI: A historical perspective and future directions
Maillard, P., Fletcher, E. M., Carmichael, O. T., Schwarz, C. G., Seiler, S., DeCarli, C. S., & Initiative, A. D. N. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14358 · Cited by 17
APOE ε4–associated heterogeneity of neuroimaging biomarkers across the Alzheimer's disease continuum
Mares, J. A., Kumar, G., Sharma, A., Emrani, S., McIntire, L. B., Guo, J., Menon, V., Nuriel, T., & Initiative, A. D. N. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14392 · Cited by 16
Zhou, X., Kedia, S., Meng, R., & Gerstein, M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0312848 · Cited by 14
Generative AI-Driven Classification of Alzheimer’s Disease Using Hybrid Transformer Architectures
Kumar, S. D. (2025) · IEEE International Symposium on Technology and Society (ISTAS) · doi:10.1109/istas65609.2025.11269635 · Cited by 13
Plasma Amyloid- β and Alzheimer’s Disease-Related Changes in Late-Life Depression
Yamazaki, C., Tamaoki, T., Nunomura, A., Tamai, K., Yasuda, K., & Motohashi, N. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170111 · Cited by 13
On the Initialization of Long Short-Term Memory Networks
Ghazi, M. M., Nielsen, M., Pai, A., Marc Modat, A., Cardoso, M. J., Sebastien Ourselin, A., & Sørensen, L. (2019) · Lecture notes in computer science · doi:10.1007/978-3-030-36708-4_23 · Cited by 15
Alber, J., Maruff, P. T., Santos, C. Y., Ott, B. R., Salloway, S., Yoo, D. C., Noto, R. B., Thompson, L. I., Goldfarb, D., Arthur, E., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00599-1 · Cited by 13
Fifty Years of Radiopharmaceuticals.
Brugarolas, P., Comstock, J., Dick, D., et al. (2020) · PubMed · Cited by 13
Initiative, T. A. D. N., Wang, M., Yan, Z., Zhang, H., Lu, J., Li, L., Yu, J., Wang, J., Matsuda, H., Zuo, C., et al. (2020) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-20-110 · Cited by 13
Kamli, A., Saouli, R., Batatia, H., Naceur, M. B., & Youkana, I. (2020) · IET Image Processing · doi:10.1049/iet-ipr.2020.1141 · Cited by 13
Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory
Lewczuk, P., Wiltfang, J., Kornhuber, J., & Verhasselt, A. (2021) · Diagnostics · doi:10.3390/diagnostics11122372 · Cited by 13
Ge, X., Initiative, A. D. N., Qiao, Y., Choi, J., Raman, R., Ringman, J. M., & Shi, Y. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215555 · Cited by 14
Coker-Ayo, O. O., Nathaniel, S. I., Poupore, N. S., Bailey-Taylor, M. J., Roley, L. T., Goodwin, R. L., McPhail, B. T., Russ‐Sellers, R., & Nathaniel, T. I. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.828782 · Cited by 13
Sun, Y., Initiative, A. D. N., Hu, H., Hu, H., Huang, L., Tan, L., & Yu, J. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221207 · Cited by 13
Allwright, M., Mundell, H. D., Sutherland, G. T., Austin, P. J., & Guennewig, B. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285416 · Cited by 14
Whole Person Modeling: a transdisciplinary approach to mental health research
Felsky, D., Cannitelli, A., & Pipitone, J. (2023) · Discover Mental Health · doi:10.1007/s44192-023-00041-6 · Cited by 16
“…Medicines Partnership® Program for Alzheimer’s Disease (AMP-AD)), the Alzheimer’s Disease Neuroimaging Initiative (ADNI; target n = 2000) [112], the Adolescent Brain and Cognitive Development Study (ABCD; n = 11,880) [113], the Dunedin Study (n = 1037) [114], the multigenerational…”
BackgroundZhang, B., Zhang, X., Zhang, F., Li, M., Schwarz, C. G., Zhang, J., Yin, Z., Qian, L., Zhao, H., Wang, K., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140882 · Cited by 13
Putative CSF protein biomarker candidates for amnestic mild cognitive impairment
Counts, S., & Mufson, E. J. (2010) · Translational Neuroscience · doi:10.2478/v10134-010-0004-0 · Cited by 13
Jiang, S., Yang, W., Qiu, Y. L., & Chen, H. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150302160145 · Cited by 13
Heymann, P., Gienger, R., Hett, A., Müller, S., Laske, C., Robens, S., Ostermann, T., & Elbing, U. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170946 · Cited by 13
Poptsi, E., Tsatali, M. S., Agogiatou, C., Bakoglidou, E., Batsila, G., Dellaporta, D., Kounti, F., Liapi, D., Lysitsas, K., Markou, N., et al. (2021) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887211016057 · Cited by 13
Initiative, A. D. N., de Souza, M. B. R., de Araújo, G. S., Costa, I. G., & de Oliveira, J. R. M. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0667-6 · Cited by 12
Fardo, D. W., Katsumata, Y., Kauwe, J. S. K., Deming, Y. K., Harari, O., Cruchaga, C., & Nelson, P. T. (2017) · Experimental Gerontology · doi:10.1016/j.exger.2017.01.025 · Cited by 12
Metadata
- Authors
- Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., Trojanowski, J. Q., & Weiner, M. W.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- Neurology
- Published
- 2010-01-19
- Volume
- 74
- Issue
- 3
- Pages
- 201-209
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC2809036
- OpenAlex
- W2122328291
- Cited by
- 2,572
- References
- 27
- Citations by year
- 2026: 312 · 2025: 391 · 2024: 327 · 2023: 254 · 2022: 233 · 2021: 209 · 2020: 182 · 2019: 121 · 2018: 85 · 2017: 67 · 2016: 71 · 2015: 66 · 2014: 45 · 2013: 63 · 2012: 59
- FWCI
- 26.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (submittedVersion)
- PubMed Central (submittedVersion)
- Funders
- Alzheimer's Disease Neuroimaging Initiative (AG024904)
- National Institutes of Health (5r01ag027984-03, 5r01ag030048-05, n01mh22005-16-0-1, 5r01dk075128-05, 5u01ag006786-38, 5r01mh083552-05, 5r01ca104573-05, 5p30ag010124-30, 5p01ag009215-20, 5r01ag011378-25, 5p41rr023953-04, 5u01ag024904-10, 5u01ag029213-05, 5r01ag016381-08, 5r01eb006266-04, 5r01ag010897-27, AG024904, 5p01ag019724-23, 5p30ca093373-23, 5p50ag016574-20)
- National Institute on Aging (AG027984, U01-AG-024904, R01AG11378, P30AG010129, U19 AG010483, U01‐AG10483, R01-AG030048, P50‐AG16574, P01 & AG019724, U01AG06786, P50-AG23501, RC1AG035427, AG 010483, R01AG031224, AG031224, P01 AG 17586-10, 1 U01 AG024904, AG 024904, UO1AG029213-01, P30AG036468, 2 P50 AG016570, 1 U01 AG 024904-05, P30 AG 10124-18, R01 AG031252, P01AG017586, U01AG010483, 1 U01 AG24904, 1P01 AG-19724-07, R01AG027859, P50AG023501, AG027859, P01 AG012435, AG-11378, 2P50AG005133, RC2AG036535, P01-AG19724, P01 AG 09215-20, R01-AG 10897, 2P30AG10129, R01 AG029672, R01 AG16381)
- National Heart, Lung, and Blood Institute (HL-095089, R01HL095089)
- National Institute of Mental Health (U01MH083506, MH 22005, MH062512, MH083506, R01MH079752, R01MH069433, MH083552, MH079752, R01 MH069259, 5 R01 MH071940, MH069433, R01MH072641, P30MH062512)
- National Institute on Drug Abuse (1 R01 DA017830)
- National Cancer Institute (2 P30 CA93373, CA104573)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK075128)
- National Institute of Neurological Disorders and Stroke (1 R01 NS050792, RL1NS062412, P50NS053488, 1 R01 NS049194, RC2NS069368, R01NS031966)
- National Institute of Biomedical Imaging and Bioengineering (1 U54 EB05149, 1 R01 EB 006266-01, U54EB005149, P01EB001955, 5R01EB002138-07)
- U.S. National Library of Medicine (2 R01LM005639)
- National Center for Research Resources (5 P41 RR013642, P41 RR-023953, U24RR021760, U54RR021813, R24 RR021382, R24 RR021992, KL2RR024144)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD050735, 1R01 HD053893-01)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, mild cognitive impairment, neuroimaging biomarkers, cerebrospinal fluid biomarkers, amyloid-beta 42, longitudinal cognitive change, normal aging, memory impairment, ADAS-Cog
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cross-Sectional Studies, Diagnostic Imaging, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
